Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$0.55.

  • Alaunos Therapeutics' EPS (Basic) rose 2142.86% to -$0.55 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.31, marking a year-over-year increase of 6861.41%. This contributed to the annual value of -$3.01 for FY2024, which is 8632.16% up from last year.
  • Alaunos Therapeutics' EPS (Basic) amounted to -$0.55 in Q3 2025, which was up 2142.86% from -$0.63 recorded in Q2 2025.
  • In the past 5 years, Alaunos Therapeutics' EPS (Basic) registered a high of -$0.04 during Q3 2022, and its lowest value of -$5.49 during Q2 2023.
  • For the 5-year period, Alaunos Therapeutics' EPS (Basic) averaged around -$1.33, with its median value being -$0.63 (2023).
  • As far as peak fluctuations go, Alaunos Therapeutics' EPS (Basic) tumbled by 1315000.0% in 2023, and later skyrocketed by 9037.74% in 2024.
  • Over the past 5 years, Alaunos Therapeutics' EPS (Basic) (Quarter) stood at -$0.06 in 2021, then tumbled by 4033.33% to -$2.48 in 2022, then tumbled by 97.58% to -$4.9 in 2023, then skyrocketed by 90.38% to -$0.47 in 2024, then fell by 16.65% to -$0.55 in 2025.
  • Its EPS (Basic) was -$0.55 in Q3 2025, compared to -$0.63 in Q2 2025 and -$0.67 in Q1 2025.